• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

Share:

October 4, 2022

Highlights on this story:
  • Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2
  • LRRK2 mutations are one of the most common genetic drivers of Parkinson’s disease
  • Targeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease

Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122 (DNL151), as compared to placebo in approximately 400 participants with Parkinson’s disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene.

The primary endpoint of the LIGHTHOUSE study is time to confirmed worsening, as assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) over the treatment period, up to 180 weeks. Participants will be randomized to receive oral BIIB122 or placebo once daily.

“Mutations in the LRRK2 gene comprise the most frequent mutations found in Parkinson’s disease, indicating that LRRK2 inhibition may be a promising therapeutic approach to the disease,” said Samantha Budd Haeberlein, Ph.D., Head of Neurodegeneration Development at Biogen. “The LIGHTHOUSE study will specifically recruit individuals with a pathogenic mutation in LRRK2, enabling us to test the genetic hypothesis and implicated lysosomal pathway. The LIGHTHOUSE study is the largest study ever undertaken in individuals with Parkinson’s disease caused by a LRKK2 mutation.”

BIIB122 is an investigational small molecule inhibitor of LRRK2 that was discovered and initially developed by Denali. Denali and Biogen are co-developing and co-commercializing BIIB122 for the potential treatment of Parkinson’s disease.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“In collaboration with Biogen, we are excited to be pursuing the potential of LRRK2 inhibition as an effective treatment for Parkinson’s disease,” said Carole Ho, M.D., Chief Medical Officer of Denali. “The initiation of the Phase 3 LIGHTHOUSE study marks an important milestone in the BIIB122 development program. Together with the recent initiation of the Phase 2b LUMA study in early-stage Parkinson’s disease, we hope to have the opportunity to bring a novel therapeutic option to people living with Parkinson’s disease.”

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • InterSystems Announces Clean Data as a SolutionInterSystems Announces Clean Data as a Solution
  • Venture Builder Studio 11.2 Ventures Acquires Assets of K8 Ventures to Accelerate Growth of AI-Based Portfolio CompaniesVenture Builder Studio 11.2 Ventures Acquires Assets of K8 Ventures to Accelerate Growth of AI-Based Portfolio Companies
  • Open APIs in Healthcare: The Future of Data Integration ReportOpen APIs in Healthcare: The Future of Data Integration Report
  • Fitbit Reportedly Looking For Buyer After Slashing 2019 Revenue ForecastFitbit Reportedly Looking For Buyer After Slashing 2019 Revenue Forecast
  • Akorn Announces Agreement to Sell Its Consumer Health Business to Prestige Consumer HealthcareAkorn Announces Agreement to Sell Its Consumer Health Business to Prestige Consumer Healthcare
  • Gemini Therapeutics and Disc Medicine Announce Merger AgreementGemini Therapeutics and Disc Medicine Announce Merger Agreement
  • Walmart Begins Selling Health Plans in Time for Medicare’s Annual Enrollment PeriodWalmart Begins Selling Health Plans in Time for Medicare’s Annual Enrollment Period
  • Plume Raises $24M for Gender-Affirming Virtual Care to Support Trans & Gender Diverse CommunityPlume Raises $24M for Gender-Affirming Virtual Care to Support Trans & Gender Diverse Community

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications